HOOKIPA Pharma to Present at Piper Jaffray 31st Annual Healthcare Conference
26 November 2019 - 12:00AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics targeting infectious diseases and
cancers based on its proprietary arenavirus platform, today
announced that HOOKIPA’s management team will present and host
one-on-one meetings at Piper Jaffray 31st Annual Healthcare
Conference, taking place December 3-5, 2019 in New York:
- Presentation: Tuesday, December 3, 2019 at
12:10 p.m. ET, Staten Island Track, Kennedy 1, 4th
Floor
A live audio webcast of the presentation held at the Piper
Jaffray Healthcare Conference will be available within the
Investors & Media section of HOOKIPA’s website at
https://ir.hookipapharma.com/events. An archived replay will be
accessible for 30 days following the event.
About
HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical
stage biopharmaceutical company developing a new class of
immunotherapeutics, targeting infectious diseases and cancers based
on its proprietary arenavirus platform that is designed to
reprogram the body’s immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, VaxWave®*, a replication-deficient viral vector, and
TheraT®*, a replication-attenuated viral vector, are designed to
induce robust antigen specific CD8+ T cells and
pathogen-neutralizing antibodies. Both technologies are designed to
allow for repeat administration to augment and refresh immune
responses. TheraT® has the potential to induce CD8+ T cell response
levels previously not achieved by other immuno-therapy approaches.
HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in
vivo to activate the immune system.
HOOKIPA’s VaxWave®-based prophylactic
cytomegalovirus vaccine candidate is currently in a Phase 2
clinical trial in patients awaiting kidney transplantation from
living cytomegalovirus-positive donors. To expand its infectious
disease portfolio, HOOKIPA has entered into a collaboration and
licensing agreement with Gilead Sciences, Inc. to jointly research
and develop functional cures for HIV and Hepatitis B
infections.
In addition, HOOKIPA is building a proprietary
immuno-oncology pipeline by targeting virally mediated cancer
antigens, self-antigens and next-generation antigens. The TheraT®
based lead oncology product candidates, HB-201 and HB-202, are in
development for the treatment of Human Papillomavirus-positive
cancers. The Phase 1/2 clinical trial initiation for HB-201 is
still planned in 2019. The HB-202 IND filing is intended for the
first half of 2020.
Find out more about HOOKIPA online at
www.hookipapharma.com.
*Registered in Europe; Pending in the US.
For further information, please contact:
MediaNina Waibel Senior Director -
Communications Nina.Waibel@HookipaPharma.com
InvestorsMatt BeckExecutive Director – Investor
RelationsMatthew.Beck@HookipaPharma.com
Media enquiries Sue Charles/ Ashley Tapp
Instinctif PartnersHookipa@Instinctif.com +44 (0)20 7457 2020
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Apr 2024 to May 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From May 2023 to May 2024